DENND4C Inhibitors
DENND4C inhibitors represent a class of chemical compounds designed to specifically target and modulate the activity of the DENND4C protein. DENND4C, also known as connecdenn 3, is a protein that plays a pivotal role in intracellular vesicle trafficking and membrane dynamics within eukaryotic cells. These inhibitors are engineered to interfere with DENND4C's function, impacting its involvement in cellular processes such as endocytosis, vesicle formation, and Golgi apparatus organization.
The mechanism of action of DENND4C inhibitors primarily revolves around their ability to disrupt DENND4C's guanine nucleotide exchange factor (GEF) activity. DENND4C functions as a GEF for the small GTPase ARF1, a critical regulator of vesicle formation and trafficking. DENND4C activates ARF1 by catalyzing the exchange of GDP for GTP, facilitating ARF1's attachment to membranes and its involvement in vesicle budding. DENND4C inhibitors, therefore, work by either directly inhibiting this GEF activity or interfering with the protein-protein interactions that DENND4C requires for its function. By doing so, they disrupt the normal cycling of ARF1 and subsequently impede vesicle formation and trafficking, causing alterations in membrane dynamics and the structural organization of cellular compartments such as the Golgi apparatus. This disruption can have broad implications for cellular homeostasis and signaling, making DENND4C inhibitors valuable tools for researchers studying intracellular transport and membrane-related processes in various biological contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A inhibits DENND4C by disrupting vesicular trafficking processes, blocking its localization to the Golgi apparatus, and impeding its function in vesicle formation. | ||||||
SecinH3 | 853625-60-2 | sc-203260 | 5 mg | $273.00 | 6 | |
SecinH3 targets DENND4C by inhibiting its guanine nucleotide exchange factor (GEF) activity, thus reducing the activation of Rab GTPases and impairing vesicle trafficking. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $187.00 $670.00 | 11 | |
Golgicide A inhibits DENND4C through disrupting its binding to the Golgi apparatus, leading to vesicle trafficking defects and impaired cellular transport processes. | ||||||
Exo1 | 461681-88-9 | sc-200752 sc-200752A | 10 mg 50 mg | $82.00 $291.00 | 4 | |
Exo1 inhibits DENND4C by blocking its interaction with SNX5 and SNX6, crucial components of endosomal sorting complexes, resulting in altered endosomal trafficking pathways. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $87.00 | 44 | |
Dynasore inhibits DENND4C by disrupting dynamin-mediated endocytosis, affecting the recycling of membrane components, and subsequently impairing vesicular trafficking dynamics. | ||||||
Pitstop 2 | 1419093-54-1 | sc-507418 | 10 mg | $360.00 | ||
Pitstop 2 targets DENND4C by inhibiting clathrin-mediated endocytosis, disrupting receptor internalization, and impacting vesicle formation and cellular transport processes. | ||||||
Dynamin Inhibitor II | 1119-97-7 | sc-203931 sc-203931A sc-203931B sc-203931C | 5 g 250 g 500 g 1 kg | $46.00 $82.00 $122.00 $194.00 | ||
Dynamin Inhibitor II inhibits DENND4C by interfering with ARF6 activation, leading to disrupted vesicle trafficking and impaired recycling of membrane proteins, thus affecting cellular processes. | ||||||
2-(Benzoylcarbamothioylamino)-5,5-dimethyl-4,7-dihydrothieno[2,3-c]pyran-3-carboxylic Acid | 314042-01-8 | sc-503400 | 10 mg | $300.00 | ||
CID 1067700 inhibits DENND4C by disrupting its interaction with GTP-bound ARF1, blocking the activation of ARF1 and impairing vesicle trafficking and Golgi apparatus function. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $134.00 $502.00 | 7 | |
ML141 inhibits DENND4C by selectively inhibiting its GEF activity toward ARF1, disrupting vesicle trafficking processes and affecting Golgi apparatus function and membrane dynamics. | ||||||